{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"}],"title":"yes"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"32"}],"title":"no"}],"title":"Objective Response rate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"5"}],"title":"yes"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"29"}],"title":"no"}],"title":"Clinical Benefit rate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"34"}],"units":"Participants"}],"description":"sCR:CR+normal FLC+absence of clonal cells in BM; CR:Negative immunofixation,disappearance of soft tissue plasmacytomas +≤5% plasma cells in BM+normal FLC; VGPR:M-protein detectable by immunofixation,not on electrophoresis or 90% or greater reduction in serum M-protein+urine M-protein level \\<100mg per 24h,\\>90% decrease in the difference between involved/uninvolved FLC; PR:≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to \\<200 mg per 24 h or ≥50% decrease in the difference between involved/uninvolved FLC or ≥50% reduction in plasma cells, provided baseline bone marrow plasma cell percentage was ≥30%, ≥50% size reduction of soft tissue plasmacytomas; MR:25%-49% reduction of serum M-protein+reduction in 24h urinary M-protein by 50-89%(still \\>200 mg/24h),25-49% soft tissue plasmacytomas size reduction,no increase in size or number of lytic bone lesions; SD:no response or PD ORR: %of subjects with MR+PR+VGPR+CR+sCR CBR:ORR + %of subjects with SD.","groups":[{"description":"40 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG000","title":"BT062 40 mg/m²"},{"description":"50 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG001","title":"BT062 50 mg/m²"},{"description":"65 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG002","title":"BT062 65 mg/m²"},{"description":"80 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG003","title":"BT062 80 mg/m²"},{"description":"100 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG004","title":"BT062 100 mg/m²"},{"description":"120 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG005","title":"BT062 120 mg/m²"},{"description":"140 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG006","title":"BT062 140 mg/m²"},{"description":"160 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG007","title":"BT062 160 mg/m²"},{"description":"BT062 administration (all dose levels)","id":"OG008","title":"Total"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"ITT: The Intention-to-treat (ITT) population included all subjects who were enrolled in the study and received at least 1 dose of BT062 and who had any post-Baseline evaluations or data. One subject did not have at least one post-injection assessment of the treatment response and was excluded from both the ITT and PP populations (n = 34).","reportingStatus":"POSTED","timeFrame":"On day 1 of each treatment cycle (on a monthly basis) starting with first study drug administration until Close Out visit (average 3.84 months).","title":"Anti-tumor Activity of BT062 in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma by Number of Participants With Objective Response(ORR) and/or Clinial Benefit(CBR) Based on the International Myeloma Working Group Uniform Response Criteria","type":"SECONDARY","unitOfMeasure":"Participants"}